Abstract
Early non-invasive and reliable biomarkers are among the major unmet needs in Parkinson’s disease (PD), in order to monitor therapy response and disease progression. Technology-based objective measures of motor performances could allow a deeper phenotyping of early stage motor changes which could be useful to identify frailer PD patients. Our aim is to identify early prognostic biomarkers in newly diagnosed PD patients and objectively quantify therapy-response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
